A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
In this trial, the question is addressed if zoledronic acid (Zometa, Novartis Pharma)could be
of clinical benefit for patients with myelofibrosis and myeloid metaplasia (MMM).